Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Jun 14, 2023

BUY
$6.04 - $9.66 $14,049 - $22,469
2,326 New
2,326 $17.5 Million
Q2 2022

Jun 20, 2023

BUY
$4.99 - $8.96 $11,606 - $20,840
2,326 New
2,326 $14,000
Q1 2022

Jun 20, 2023

BUY
$3.84 - $9.74 $8,931 - $22,655
2,326 New
2,326 $19,000
Q1 2022

Mar 30, 2023

SELL
$3.84 - $9.74 $23,036 - $58,430
-5,999 Reduced 72.06%
2,326 $19,000
Q1 2022

May 12, 2022

BUY
$3.84 - $9.74 $8,931 - $22,655
2,326 New
2,326 $19,000
Q1 2021

May 14, 2021

SELL
$8.44 - $12.66 $70,263 - $105,394
-8,325 Closed
0 $0
Q4 2020

Jun 22, 2023

BUY
$7.98 - $12.29 $66,433 - $102,314
8,325 New
8,325 $102,000
Q3 2020

Jun 26, 2023

BUY
$7.96 - $12.42 $66,267 - $103,396
8,325 New
8,325 $67,000
Q2 2020

Jun 26, 2023

BUY
$5.4 - $13.37 $44,955 - $111,305
8,325 New
8,325 $79,000
Q2 2020

Mar 30, 2023

BUY
$5.4 - $13.37 $1,458 - $3,609
270 Added 3.35%
8,325 $79,000
Q2 2020

Aug 14, 2020

BUY
$5.4 - $13.37 $44,955 - $111,305
8,325 New
8,325 $80,000
Q1 2020

May 15, 2020

SELL
$4.91 - $14.7 $39,550 - $118,408
-8,055 Closed
0 $0
Q4 2019

Jul 12, 2023

BUY
$9.77 - $15.66 $78,697 - $126,141
8,055 New
8,055 $120,000
Q4 2019

Mar 30, 2023

SELL
$9.77 - $15.66 $10,590 - $16,975
-1,084 Reduced 11.86%
8,055 $120,000
Q4 2019

Feb 14, 2020

SELL
$9.77 - $15.66 $10,590 - $16,975
-1,084 Reduced 11.86%
8,055 $120,000
Q3 2019

Jul 12, 2023

BUY
$9.59 - $12.0 $87,643 - $109,668
9,139 New
9,139 $93,000
Q3 2019

Mar 30, 2023

BUY
$9.59 - $12.0 $87,643 - $109,668
9,139 New
9,139 $93,000
Q3 2019

Nov 14, 2019

BUY
$9.59 - $12.0 $87,643 - $109,668
9,139 New
9,139 $94,000
Q2 2019

Jul 12, 2023

BUY
$9.54 - $14.96 $19,013 - $29,815
1,993 New
1,993 $21.1 Million

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $418M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.